New drug combo aims to tame chronic hepatitis b in landmark trial

NCT ID NCT06092333

First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests whether combining two drugs, VIR-2218 and peginterferon alfa-2a, can lower hepatitis B virus levels in people with mild or inactive chronic infection. About 50 adults aged 18 to 65 will receive monthly VIR-2218 shots for 6 months and weekly peginterferon shots for 6 months, with hospital stays for liver biopsies. The goal is to see if the combination can reduce the virus and improve the body's immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.